C4 Therapeutics : CTOS 2023 - CFT8634 Phase 1 Dose Escalation -November 01, 2023 at 07:19 am EDT

Initial Results From A Phase 1 Study of CFT8634, A Novel Bifunctional Degradation Activating Compound of BRD9, in Synovial Sarcoma and SMARCB1-Null Tumors

...

Related Keywords

Dublin ,Ireland ,Ammax Bio ,Daiihi Sankyo ,Daiichi Sankyo ,Eli Lilly ,Jazz Pharmaceuticals ,Sarcoma Alliance For Research ,Amgen ,Serono ,Glaxosmithkline ,Ayala Pharmaceuticals ,Therapeutics Inc ,Certis Oncology Solutions ,Medtronic ,Salarius Pharmaceuticals ,Threshold Pharmaceuticals ,Health Advances ,Kowa Research Institute ,Humans In Health ,Research To Practice ,Desmoid Tumor Research Foundation ,Theseus Pharmaceuticals ,Novartis ,Boehringer Ingelheim ,Novo Holdings ,Pfizer ,Astrazeneca ,Eastern Cooperative Oncology Group ,Servier Pharmaceuticals ,Common Terminology Criteria ,Adverse Events ,Positron Emission Tomography ,Computed Tomography ,Response Evaluation Criteria ,Solid Tumors ,Sucrose Non Fermentable ,Protein Degrader ,Atropos Therapeutics ,Cogent Biosciences ,Connecting Humans ,Foghorn Therapeutics ,Bavarian Nordic ,Works Therapeutics ,Repare Therapeutics ,Springworks Therapeutics ,Immune Design ,Karyopharm Therapeutics ,Sarcoma Alliance ,Advenchen Laboratories ,Cellestia Biotech ,Immix Biopharma ,Blueprint Medicines ,Trillium Therapeutics ,Monopar Therapeutics ,Bionest Partner ,Targeted Oncology ,Modular Platform ,Targeted Therapeutic Delivery ,Ligand Drug Conjugates ,Antitumor Compounds ,Red Nucleus ,Markets ,